Previous 10 | Next 10 |
NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) announces dosing of the first patient in the second cohort of patients to receive a single dose of Decoy20 in the INDP-D101 trial. This cohort dose is ...
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25 th Annual Global Investment Conference. The conference is being held on Septemb...
2023-08-14 09:07:38 ET Indaptus Therapeutics press release ( NASDAQ: INDP ): Q2 GAAP EPS of -$0.39. As of June 30, 2023, the Company had cash, cash equivalents and marketable securities of approximately $19.7 million as compared to $26.4 million as of December 31, 2022. ...
NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update. “We have recently announced t...
C ohort 1 p atients exhibit ed a significant immune response consistent with the mechanism of action Safety Review Committee approved continuation to the next cohort of patients NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Indap...
NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announces the appointment of Roger Waltzman, M.D. as its Chief Medical Officer, effective August 7, 2023....
NEW YORK, June 15, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced today that CEO Jeffrey A. Meckler will participate in the Maxim Group Virtual Healthcare C...
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced today that CEO Jeffrey A. Meckler will present a corporate overview at the Jefferies Health...
2023-05-11 12:16:34 ET Indaptus Therapeutics press release ( NASDAQ: INDP ): Q1 GAAP EPS of -$0.51. As of March 31, 2023, the Company had cash and cash equivalents and marketable securities of approximately $21.7 million. For further details see: Indaptus Therape...
NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update. “Following the dosing and com...
News, Short Squeeze, Breakout and More Instantly...
Indaptus Therapeutics Inc. Company Name:
INDP Stock Symbol:
NASDAQ Market:
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pionee...
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces today that Jeffrey Meckler, Chief Executive Officer, and Roger Waltzman, M.D., M.B.A., ...
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces data from a poster being presented at the American Society of Clinical Oncology A...